Table 5. Ongoing clinical trials of first- and second-generation EGFR TKIs in combination with anti-angiogenic therapies in EGFR-mutant NSCLC patients.
| ClinicalTrials.gov identifier or other identifier | Phase; population | Treatment | Status |
|---|---|---|---|
| UMIN000017069 | Phase III; 1st-line; NEJ026 | Erlotinib + bevacizumab vs. erlotinib | Recruiting |
| NCT02633189 | Phase III; 1st-line; BEVERLY | Erlotinib + bevacizumab vs. erlotinib | Recruiting |
| NCT00436332 | Phase II; EGFR TKI-naive; BAC1 and ADENOBAC2; S0635 | Erlotinib + bevacizumab | Ongoing, not recruiting |
| NCT02655536 | Phase II; with brain metastases; EGFR TKI-naive; BRILLIANT | Erlotinib + bevacizumab vs. erlotinib | Recruiting |
| NCT02411448 | Phase III; EGFR TKI-naive; RELAY | Erlotinib + ramucirumab vs. erlotinib (part A and B); gefitinib + ramucirumab vs. gefitinib (part C) | Recruiting |
| NCT03461185 | Phase II; EGFR TKI-pretreated (stable disease for at least 2 months | Erlotinib or gefitinib + anti-angiogenic drugs (endostatin3 or apatinib4 or anlotinib5) vs. erlotinib or gefitinib | Not yet recruiting |
| NCT03050411 | Phase I; EGFR TKI-pretreated | Erlotinib + apatinib4 | Recruiting |
| NCT03628521 | Phase I; EGFR TKI-naive patients | Erlotinib + apatinib4 (arm A) | Recruiting |
| NCT03602027 | Phase I; EGFR TKI-naive patients | Gefitinib + apatinib4 | Not yet recruiting |
1BAC, bronchioloalveolar carcinoma; 2ADENOBAC, adenocarcinoma with BAC features; 3endostatin, naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen with anti-angiogenic activity; 4anlotinib, receptor tyrosine kinase (RTK) inhibitor (including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3); 5apatinib (also known as YN968D1), TKI against VEGFR2. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.